Quanterix Corp
NASDAQ:QTRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Quanterix Corp
Free Cash Flow
Quanterix Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Quanterix Corp
NASDAQ:QTRX
|
Free Cash Flow
-$79.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Free Cash Flow
$6.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Free Cash Flow
$5.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Waters Corp
NYSE:WAT
|
Free Cash Flow
$539.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Free Cash Flow
$993m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Free Cash Flow
$2.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
Quanterix Corp
Glance View
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.
See Also
What is Quanterix Corp's Free Cash Flow?
Free Cash Flow
-79.8m
USD
Based on the financial report for Dec 31, 2025, Quanterix Corp's Free Cash Flow amounts to -79.8m USD.
What is Quanterix Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-24%
Over the last year, the Free Cash Flow growth was -107%. The average annual Free Cash Flow growth rates for Quanterix Corp have been -10% over the past three years , -24% over the past five years .
